This is the case of CAdTrio, which combines an OAd with a HD-Ad expressing a cytokine (IL-2), a checkpoint blocker (anti-PD-L1 mAb), and a bispecific tumor-targeted T-cell engager (BiTE) molecule recognizing CD3 on T cells and CD44 variant 6, a molecule widely expressed on tumors but not in normal tissues [115]. This evidence concerns the gene CD274 and neoplasm.